Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GPR142 | Q7Z601 | 5/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15967935 | 0.85 | ACACB (0.39) | CYP3A4 | |
| SCHEMBL893121 | 0.85 | ACACB (0.39) | CYP3A4 | |
| SCHEMBL893583 | 0.80 | GPR142 (0.43) | CYP3A4GPR142 | |
| SCHEMBL4248616 | 0.80 | CYP3A4 (0.37) | SLC6A3CYP3A4PARP15PARP10TDP1 | |
| SCHEMBL4248614 | 0.80 | CYP3A4 (0.37) | SLC6A3CYP3A4PARP15PARP10TDP1 | |
| SCHEMBL894363 | 0.74 | TDP1 (0.40) | CYP3A4TDP1GPR142 | |
| SCHEMBL14119112 | 0.74 | CYP3A4 (0.43) | CYP3A4 | |
| SCHEMBL4245411 | 0.72 | CYP3A4 (0.46) | CYP3A4TDP1 | |
| SCHEMBL4957591 | 0.72 | EPHX1 (0.46) | — | |
| SCHEMBL4957664 | 0.72 | EPHX1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243340-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBVIE INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120083490-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083490-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | SLC6A3 878/4885CYP3A4 8/4885PARP15 2206/4885 |
| US-20140243340-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | SLC6A3 878/4885CYP3A4 8/4885PARP15 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.